In a deal worth $2.4 billion in cash, Eli Lilly and Co. agreed to acquire Dice Therapeutics Inc., gaining a franchise of oral IL-17 inhibitors for chronic autoimmune diseases.
Sino Biopharmaceutical Ltd. formed a partnership with Gmax Biopharm International Ltd. to develop obesity candidate GMA-106. As part of the $57 million deal, Sino Biopharm acquired greater China rights to develop and commercialize the drug, in exchange for up-front and milestone payments to Gmax.
Astellas Pharma Inc. has agreed to pay Cullgen Inc. up to $1.9 billion-plus to jointly develop multiple protein degraders. Under the agreement, Tokyo-based Astellas will pay Cullgen, of San Diego, $35 million up front, and an additional $85 million if it decides, during the initial stages of development, to jointly commercialize and promote Cullgen’s lead program, a cell cycle protein degrader for the treatment of breast cancer and other solid tumors, in the U.S.
After a licensing deal with Galvanize Therapeutics Inc., Energenx Medical Ltd. will develop and commercialize pulsed electric field therapies for chronic obstructive pulmonary disease (COPD) in Mainland China, Hong Kong, Taiwan and Macau, where there is a significant need. The deal could also be the basis for future exports out of China as Energenx develops its own products.
Becton, Dickinson and Co. (BD) agreed to sell its Surgical Instrumentation platform to Steris plc for $540 million in keeping with the company’s corporate strategy to simplify its product portfolio by 2025. The divestiture includes the V. Mueller, Snowden-Pencer and Genesis products as well as three dedicated manufacturing facilities. Steris will also pick up about 360 employees with the platform. The companies expect the all-cash transaction to close by Sept. 30, 2023, pending regulatory approval.
Regulatory T-cell specialist Quell Therapeutics Ltd. has sealed a potential $2 billion agreement under which Astrazeneca plc is taking rights to two autologous Treg cell therapies for treating inflammatory bowel disease (IBD) and type 1 diabetes. Quell will receive $85 million up front, the majority of which is in cash, with a modest (undisclosed) equity investment. Reaching the $2 billion headline figure will involve a series of development and commercial milestones and royalties on sales.
Sino Biopharmaceutical Ltd. formed a partnership with Gmax Biopharm International Ltd. to develop obesity candidate GMA-106. As part of the $57 million deal, Sino Biopharm acquired greater China rights to develop and commercialize the drug, in exchange for up-front and milestone payments to Gmax.
Biopharma deal values are continuing to track at a similar pace to last year, down only 0.31% compared to the first five months of 2022, while there have been 173 fewer deals. M&A values are at their lowest value in all years tracked by BioWorld (2016-2023).
In the first five months of 2023, med-tech deal value is at the highest amount in recent years – up 128.219% from last year – while deal volume has decreased by 12.29%. Through May this year, 742 med-tech deals have raised a potential $5.38 billion, compared to 846 deals totalling $2.36 billion last year. The two recent years are vastly more than 2021, when through May there were 661 deals raising $386.69 million.
RSS
